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INTRODUCTION
Primary gastric lymphoma is a rare disease accounting 
1-7% of gastric malignant tumors, but accounts 60% among 
gastrointestinal tract lymphoma.
1-3 The prevalence of primary 
gastric lymphoma is increasing compared to the decreasing 
prevalence of gastric adenocarcinoma.
4,5 Around 80% of pri-
mary gastric lymphoma cases are B-cell non-Hodgkin lym-
phoma, which is divided by mucosa-associated lymphoid tis-
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sue (MALT) lymphoma and high-grade diffuse large cell lym-
phoma. Since 1983 when Isaacson and Wright
6 first establi-
shed the concept of mucosa-associated lymph originating 
from MALT, and the term MALT lymphoma became widely 
used since then. MALT lymphoma most commonly occurring 
in the stomach can be divided into a low grade MALT lym-
phoma which has dense nuclear chromatin and low grade cell 
division or a high grade MALT lymphoma which has the op-
posite findings. Low grade gastric MALT lymphoma occurs 
worldwide,
7-9 and is mostly found in gastric antrum and gas-
tric body. Endoscopic features vary from shallow ulcer to sim-
ple color change of mucosa, nodularity, and mass. Low grade 
gastric MALT lymphomas with such nonspecific endoscopic 
findings are often difficult to differentiate from benign diseas-
es, and follow-up findings after treatment also vary greatly. 
Low grade gastric MALT lymphoma was revealed to be cau-
sed by Helicobacter pylori as an immune response on the gas-
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tric mucosa. Patients with low grade gastric MALT lympho-
ma are reported to have increased H. pylori infection rate as 
high as 90%.
10,11 H. pylori eradication has now become the 
treatment of choice for low grade gastric MALT lymphoma, 
which was often treated by surgery in the past. The indication 
of follow-up after eradiation, the time point of diagnosing 
complete remission and future treatment plan when the erad-
ication was not led to the tumor regression are not clearly es-
tablished yet. We investigated factors associated with H. pylori 
infection rate and eradication success rate in patients with low 
grade gastric MALT lymphoma, and compared clinicopatho-
logical characteristics of patients who received eradication tr-
eatment to find a predictive factor of complete remission of 
the disease.
MATERIALS AND METHODS
Patients and methods
The study was performed in 39 patients who received gas-
trofibroscopy at least once among 47 patients confirmed as 
low grade gastric MALT lymphoma by endoscopic biopsy 
performed at Seoul National University Bundang Hospital 
between May 2003 and May 2010. Once low grade gastric 
MALT lymphoma was confirmed by mucosal biopsy, the se-
verity of the infiltration in gastric mucosa and nodal invasion 
were confirmed by gastric endoscopic ultrasound and the 
stage was established by abdominal computerized tomogra-
phy and bone marrow biopsy. H. pylori infection was con-
firmed by positive histology, rapid urease test, or urea breath 
test. Tumor remission was determined by follow-up upper 
gastrointestinal tract endoscopy, mucosal biopsy, and other 
imaging studies. The follow-up endoscopy was performed 
with biopsy in several tissues including from lesions pre-
sumed abnormal and from areas with normal findings. The 
clinical courses, endoscopic findings, operation records, pat-
hologic findings, imaging results, treatment course of the pa-
tients were retrospectively analyzed. The locations of lesions 
were termed proximal part from gastric fundus to mid body, 
and distal part below the lower body. The study was approved 
by the Ethics Committee at Seoul National University Bun-
dang Hospital.
Statistical analysis
Fisher’s exact test and Wilcoxon rank sum test were per-
formed for between-group comparison. Logistic regression 
analysis was performed to find factors associated with remis-
sion of lymphoma. Factors associated with the time to remis-
sion were analyzed by Kaplan-Meier method. p-value less 
than 0.05 were considered statistically significant. SPSS ver-
sion 17.0 (SPSS Inc., Chicago, IL, USA) and SAS version 9.1 
(SAS Institute Inc., Cary, NC, USA) were used for statistical 
analysis.
RESULTS
Clinicopathological characteristics of patients
There were 22 male patients and 17 female patients among 
a total of 39 patients, their mean age was 52.23±10.29 years. 
Four of them were in their 30s (10%), 12 in their 40s (31%), 
14 in their 50s (36%), 6 in their 60s (15%), and 3 in their 70s 
(8%), with 50s accounting for the biggest part. Stage 1 was the 
most common in 35 cases (90%), followed by stage 2, stage 3, 
and stage 4 in 1 case (2.5%), 2 cases (5%), and 1 case (2.5%), 
respectively (Table 1).
Endoscopic findings
Lesions with mucosal nodule or elevated lesion from mu-
cosa were most common in 20 cases (48%) while flat or de-
pressed lesion with erosion, shallow ulcer, or color change of 
Table 1. Clinicopathological Characteristics of 39 Patients
Variable No. (%)
Age, yr
Mean/Median  52.23±10.29/53
30-39   4 (10)
40-49 12 (31)
50-59 14 (36)
60-69   6 (15)
70-79 3 (8)
Sex
Male:Female 22:17 (56:44)
Stage
I 35 (90)
II    1 (2.5)
III 2 (5)
IV    1 (2.5)
Location I
Fundus 3 (8)
Body/Angle 24 (62)
Antrum 12 (30)
Location II
Proximal 11 (28)
Distal 28 (72)
Endoscopic feature
Color change/Erosion/Ulcer 18 (43)
Nodularity/Elevation 20 (48)
Fold 1 (2)
Mass/Polyp 3 (7)YJ Choi et al. 
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the mucosa were found in 18 cases (43%). Other findings in-
cluded hypertrophic fold in 1 case (2%) and mass forming le-
sion in 3 cases (7%). Lymphoma was found mostly common-
ly at gastric fundus and angle in 24 cases (62%), followed by 
gastric antrum in 12 cases (30%) and gastric fundus in 3 cases 
(8%). Lesions were more commonly detected at the distal part 
when divided by proximal and distal parts, each accounting 
for 28% (11 cases) and 72% (28 cases). The first impression of 
lesions by endoscopic findings were benign disease in 15 cas-
es (38%), early gastric cancer in 9 cases (23%), advanced gas-
tric cancer in 2 cases (5%), gastric MALT lymphoma in 12 
cases (31%) and other findings 1 case (3%). Seven cases (78%) 
among 9 cases with early gastric cancer were determined as 
flat type early gastric cancer (early gastric cancer IIc) by im-
pression. Gastric MALT lymphoma could be differentiated by 
endoscopic findings only in 41% (16/39).
Rates of positive H. pylori and eradication
Thirty (77%) among the total 39 patients were H. pylori po-
sitive, 26 patients among them received a triple therapy using 
proton pump inhibitors. Rabeprazole and esomeprazole were 
each used in 8 cases, pantoprazole in 6 cases, lansoprazole in 2 
cases, and omeprazole in 1 case for proton pump inhibitor. 
The eradication rate of first-line eradication therapy was 69% 
(18/26). Second-line eradication using proton pump inhibi-
tors, tetracycline, metronidazole, and bismuth was successful 
in all 8 patients who received the second-line therapy (Fig. 1).
Factors associated with H. pylori eradication
Success of the first-line eradication therapy was affected by 
the severity of neutrophil infiltration in mucosal tissues (p= 
0.049) (Table 2). When a linear-by-linear association was ana-
lyzed between the success of the first-line eradication therapy 
and the severity of neutrophil infiltration, the rate of success 
in the first-line therapy was increased in milder case of neu-
trophil infiltration (p=0.012) (Fig. 2). Age, stage of the disease, 
location of gastric MALT lymphoma, the degree of H. pylori, 
severity of mononuclear lymphocyte infiltration, and the de-
pth of tissue invasion were not significantly associated with 
the success of H. pylori eradication.
Treatment of low grade MALT lymphoma
Twenty-nine patients among 36 patients with stage 1 and 2 
gastric MALT lymphoma were H. pylori positive. Among 
these, 26 patients received eradication therapy, and 22 of them 
experienced tumor regression with 84.6% (22/26) remission 
rate. The remission rate was increased to 88% (22/25) when 
considering only the patients with stage 1 disease and positive 
H. pylori. When considering only the H. pylori positive pa-
tients who did not receive eradication therapy as an initial tr-
eatment, 1 patient with stage 3 disease achieved remission af-
ter chemotherapy (R-CHOP). Two patients with a past history 
of eradication therapy for 2 years before diagnosis were con-
sidered to be resistant to eradication therapy because they 
showed positive H. pylori when diagnosed of low grade gas-
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Fig. 1. Therapeutic scheme of 39 mucosa-associated lymphoid tissue (MALT) lymphoma cases at a uni-center study of Seoul National Univer-
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tric MATL lymphoma. They finally achieved R-CHOP and 
radiotherapy as an initial treatment, respectively. Another 1 
patient achieved remission after the administration of proton 
pump inhibitor but received surgery in another hospital due 
to recurrence. On the other hand, 7 out of 9 patients with neg-
ative H. pylori test had stage 1 disease. Three patients with 
stage 1 disease received eradication therapy, and 2 among 
them showed remission revealing 67% remission rate. The re-
maining 4 patients with stage 1 disease and negative H. pylori 
received radiotherapy for initial treatment, and 3 of them 
achieved remission. One patient each in stage 3 and 4 re-
ceived chemotherapy for initial treatment, but the patient 
with the stage 4 disease failed remission (Fig. 1). The remis-
sion rate in the stage I patients regardless of H. pylori infec-
tion was 86% (24/28) when only an eradication therapy was 
performed.
Factors associated with remission of lymphoma  
after eradication
A survival curve from the onset of treatment to remission 
was graphed for 28 patients who received eradication therapy 
as the initial treatment among patients with stage 1 disease 
Table 2. Clinicopathological Difference between the First Eradica-
tion Success and the Failure
Variable
First eradication 
success (n=18)
Second eradication 
success (n=8)
p-value
Age, mean
a) 49±8 54±12 0.160
Sex, 
Male:Female     9:9 (50:50)   6:2 (75:25) 0.395
Stage
IE  17 (94)   8 (100) 1.000
IIE 1 (6) 0
Location
Proximal       6 (33.3) 2 (25) 1.000
Distal     12 (66.7) 6 (75)
Endoscopic finding
Color change/
  Erosion/Ulcer 
  7 (39) 6 (75) 0.202
Nodularity/
  Elevation
11 (61) 5 (62) 1.000
Fold 1 (6) 0 1.000
Mass/Polyp 1 (6) 0 1.000
H. pylori burden
Absent  0 0 0.517
Mild 10 (56) 3 (38)
Moderate   4 (22) 2 (25)
Marked   2 (11) 2 (25)
Neutrophil 
  infiltration
Absent 1 (6) 0 0.049
Mild   2 (11) 0
Moderate 10 (56) 2 (25)
Marked   2 (11) 5 (63)
Mononuclear 
  lymphocyte
Moderate  10 (56) 4 (50) 1.000
Marked   5 (28) 3 (38)
Depth
T1   8 (44) 4 (50) 0.525
T2 1 (6) 2 (25)
Values are presented as number (%).
a)In years.
Fig. 2. Trend between the neutrophil infiltration and the eradica-
tion. The less neutrophil infiltration tends to have the higher chance 
of success in the first eradication. G1, group which achieved first 
eradication success; G2, group which obtained eradication after the 
second eradication.
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Fig. 3. Occurrence of complete remission (CR) event. Kaplan-Mei-
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(Fig. 3). Fifty percent of them achieved remission in 111± 
11.78 days. These patients were divided again into a remission 
success group and failure group to find out analyzed factors 
associated with success of remission after eradication therapy. 
Factors such as age, disease stage, location of gastric MALT 
lymphoma, load of H. pylori, H. pylori eradication by first-line 
Table 3. Clinicopathological Difference between the Remission Successors and the Failures in Stage I Patients Who Took the Eradication 
Therapy as a First Therapy
Variable
Remission
p-value HR (95% CI)
Successors (n=24)  Failures (n=4)
Age 50.08±9.35 50.25±14.24 0.531   0.99 (0.95-1.03)
Sex
Male:Female  14:10 2:2 0.330   1.50 (0.66-3.42)
Location I
Antrum   6 (25) 0
Body/Angle 16 (67) 3 (75) 0.077   0.41 (0.15-1.10)
Fundus 2 (8) 1 (25) 0.295   0.42 (0.08-2.13)
Location II
Proximal    7 (29) 2 (50)
Distal 17 (71) 2 (50) 0.345   1.54 (0.63-3.76)
Endoscopic finding
Color change 11 (46) 2 (50) 0.649   0.83 (0.37-1.86)
Nodularity/Elevation 13 (54)   4 (100) 0.153   0.55 (0.24-1.25)
Fold 1 (4) 0  0.782 0.75 (0.1-5.65)
Mass/Polyp 1 (4) 0 0.102     6.23 (0.70-55.81)
H. pylori
Positive 22 (92) 3 (75) 0.708   1.33 (0.30-5.78)
H. pylori burden
Absent 2 (8) 1 (25)
Mild 11 (46) 1 (25) 0.726     1.32 (0.29-6.067)
Moderate  5 (21) 1 (25) 0.729   1.34 (0.26-7.01)
Marked  3 (13) 1 (25) 0.824   1.23 (0.20-7.65)
First eradication
Fail   7 (29) 1 (25)
Success 15 (71) 2 (50) 0.356   0.65 (0.26-1.63)
Neutrophil infiltration
Absent 1 (4) 0
Mild 1 (4) 0 0.591   0.46 (0.03-8.05)
Moderate   9 (38) 3 (75) 0.127   0.17 (0.02-1.65)
Marked   7 (29) 0 0.280   0.29 (0.03-2.78)
Mononuclear lymphocyte
Absent 0 0
Mild 0 0
Moderate 10 (42) 3 (75)
Marked   8 (33) 0 0.518   1.37 (0.53-3.51)
Depth
T1 10 (42) 2 (50)
T2   3 (13) 0 0.369 1.504 (0.66-3.42)
Values are presented as number (%).
HR, hazard ratio; CI, confidence interval.106  Clin Endosc 2011;44:101-108
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eradication therapy, degrees of neutrophil and mononuclear 
lymphocyte infiltration, and the depth of tissue invasion were 
not significantly different between the two groups (Table 3).
Factors associated with the time to remission  
after eradication therapy
The median time from the onset of eradication therapy to 
the first remission diagnosis was 98 days (20 to 283 days) 
among 24 patients who achieved remission by eradication 
therapy. These patients were further divided into the early re-
mission group and the non-early remission group based on 
the 98 days of median time to remission in order to find fac-
tors associated with the time to remission. Factors such as age, 
disease stage, location of gastric MALT lymphoma, load of H. 
pylori, H. pylori eradication by the first eradication therapy, 
degree of mononuclear lymphocyte infiltration, and the depth 
of tissue invasion were not significantly different between the 
two groups (Table 4). The patients in early remission group 
tended to be younger at diagnosis than those in the non-early 
remission group, although not statistically significant (p= 
0.089).
Follow-up and recurrence
Follow-up endoscopy was performed at about 3-month in-
terval until remission is achieved, and every 7 months on av-
erage thereafter. The median duration of follow-up was 645 
days (127 to 2,428 days). Two patients, among 24 patients with 
remission, experienced tumor recurrence on day 219 and day 
1,327 after the first remission. These 2 patients were all con-
firmed of H. pylori reinfection, received eradication therapy 
again, and achieved remission again each on day 141 and 61 
after the onset of treatment. The median duration of follow-up 
while remaining in remission status was 119 days (0 to 2,115 
days) among 24 patients who were available for follow-up.
DISCUSSION
The remission rate of low grade gastric MALT lymphoma 
was 86% when using H. pylori eradication therapy only, which 
is higher than studies in Western countries. Furthermore, H. 
pylori eradication was more likely to succeed in a group with 
less infiltration of neutrophil. This was the first study to com-
pare two groups divided by the median time to remission in 
order to find factors associated with gastric MALT lymphoma 
remission, and this study is important in that it attempted to 
minimize errors arising from subjective observations on endo-
scopic findings with a single center study design. Significant 
difference could not be detected from statistical analysis due 
to the small sample size, which was one of limitations of this 
study. Endoscopic findings of slightly elevated lesions such as 
mucosal nodule followed by shallow mucosal lesions includ-
ing erosion, shallow ulcer, or color change were most com-
monly detected from low grade gastric MALT lymphoma in 
this study, similar to findings in previous studies.
12,13 Impres-
Table 4. Clinicopathological Difference between the Early Remis-
sion and the Late Remission
Remission Early (n=12) Late (n=12) p-value
Age, yr 46.83±9.58 53.33±8.24 0.089
Sex
Male:Female  8:4 (67:33) 6:6 (50:50) 0.408
Location I
Antrum    4 (33)   2 (17) 0.244
Body/Angle   6 (50) 10 (83)
Fundus   2 (17) 0
Location II
Proximal   2 (17)   5 (42) 0.371
Distal 10 (83)   7 (58)
Endoscopic finding
Color change   4 (33)   7 (58) 0.219
Nodularity/Elevation   6 (50)   7 (58) 0.682
Fold 0 1 (8) 1.000
Mass/Polyp 1 (8) 0 1.000
H. pylori
Positive 10 (83)   12 (100) 0.478
H. pylori burden
Absent       2 (16.5) 0 0.771
Mild   5 (42)   6 (50)
Moderate   3 (25) 2
Marked      2 (16.5) 1
First eradication
Fail    3 (25)   4 (33) 0.408
Success   7 (58)   8 (67)
Neutrophil infiltration
Absent  1 (8) 0 0.335
Mild 1 (8) 0
Moderate   5 (42)   4 (33)
Marked   2 (17)   5 (42)
Mononuclear lymphocyte
Absent  0 0 1.000
Mild 0 0
Moderate   5 (42)   5 (42)
Marked  4 (33)   4 (33)
Depth
T1   6 (50)   4 (33) 0.192
T2 0   3 (25)
Values are presented as number (%).YJ Choi et al. 
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sion or suspicion of gastric MALT lymphoma only by endo-
scopic findings accounted 41% of overall cases, suggesting the 
difficulty of differential diagnosis with other diseases.
Positive H. pylori among low grade gastric MALT lympho-
ma patients in this study were 77%, similar to levels in other 
studies.
14,15 H. pylori burden or location of lymphoma were 
not significant factors associated with eradication of H. pylori; 
cases with severe neutrophil infiltration in the tumor tissues 
were more likely to fail the first-line eradication therapy. Such 
trend was not reported yet and requires further study in more 
patients in the future.
In a meta-analysis by Zullo et al.
16 involving 1,271 patients 
in 34 studies reported 98.3% H. pylori eradication rate and 
77.8% remission rate in positive H. pylori patients after eradi-
cation therapies including 3rd, 4th, and 5th therapies. In the 
present study, eradication therapy in positive H. pylori infec-
tion patients among low grade gastric MALT lymphoma of 
stage 1 yielded 88% complete remission rate, which is a higher 
level than other studies performed in Western countries.
17-19 
Other studies performed in Korean patients reported similar 
or higher rates of complete remission after eradication therapy, 
such as the study by Lee et al.
20 which reported 82.8% of com-
plete remission rate after H. pylori eradication therapy in 55 
patients, the study by Park et al.
21 which reported 72.4% in 41 
patients, and the study by Hong et al.
22 which reported 94.4% 
in positive H. pylori infection patients with stage 1 or 2 dis-
ease. Further studies such as on genetic polymorphism are re-
quired to find an explanation regarding relatively higher rate 
of complete remission after H. pylori eradication therapy in 
Korean patients compared to Western patients.
H. pylori reinfection 6 months after successful eradication 
was found in 15% (4/26) in this study, higher than 2.7% in the 
meta-analysis by Zullo et al.
16 Two of these 4 patients experi-
enced recurrence of cancer, received the eradication therapy 
again, and obtained remission again within 6 months after 
the onset of therapy. It is suggested, from this result, that low 
grade gastric MALT lymphoma patients could achieve long-
term remission only by H. pylori eradication therapy.
23-25
Hong et al.
22 reported the median time from onset of eradi-
cation therapy to remission as 3 months, which is similar with 
this study. Other literature reporting 5 months of time to re-
mission recommended wait and see strategy from at least one 
month until 15 months.
26 Three among 4 cases without re-
mission after H. pylori eradication therapy in this study were 
decided as remission failure before reaching 12 months after 
diagnosis and result might have been different if followed for 
a longer time.
According to the currently available data, the remission rate 
after eradication therapy is about 80% when the cancer is con-
fined to mucosa and submucosal layer. Chemotherapy, radio-
therapy, or surgery should be considered when the lesion is 
not responsive to eradication therapy.
24 R-CHOP or radio-
therapy were performed in this study, each in 1 and 2 patients 
without response to the eradication therapy, achieved com-
plete remission.
There were reports that eradication therapy on negative H. 
pylori infection might yield lower remission rate.
27,28 It is now 
recommended, however, that eradication therapy should be 
first considered also for H. pylori negative low grade gastric 
MALT lymphoma patients because there is no established 
treatment of choice yet and because remission was also report-
ed after eradication therapy for some negative H. pylori infec-
tion cases.
9,13,24,27,29 We also applied eradication therapy in 3 H. 
pylori negative patients, and 2 patients among them achieved 
remission with short time to remission (36 and 88 days, re-
spectively) and this fact supports the eradication therapy as a 
treatment of choice in even H. pylori negative gastric MALT 
lymphoma patients.
Recent literature notes negative H. pylori infection, finding 
of high grade lymphoma cell, and translocations of API2 and 
MALT genes as factors associated with remission failure after 
eradication therapy.
13 Translocations of these genes were actu-
ally found in 67% cases of remission failure after eradication 
therapy in a study.
29 Future studies may evaluate the validity of 
API2-MALT gene translocation as a predictive factor. Depth 
of tissue invasion or disease stage have been also selected as 
potential predictive factors of response to eradication therapy 
in gastric MALT lymphoma,
28 but they did not show any sig-
nificant difference in this study. On the other hand, in a retro-
spective study by Kim et al.
30 in 95 patients with IE1 stage of 
disease reported that lesions in the proximal part responded 
significantly less to a treatment compared to lesions in the dis-
tal part. The univariate analysis in this study, however, could 
not find a significant difference between the two groups di-
vided by proximal or distal part based on the location of tu-
mor. We also attempted to compare clinical characteristics 
between the early remission group and the non-early remis-
sion based on the median 98 days from the onset of therapy 
to remission in order to find a factor associated with remis-
sion. It was found that the early remission group tended to be 
younger at diagnosis compared to the non-early remission 
group, although the difference was not statistically significant 
(p=0.089).
With regard to the still debated follow-up strategy after re-
mission, Hong et al.
22 reported H. pylori reinfection as a risk 
factor of recurrence. All the recurrent patients in this study 
were also reinfected by H. pylori. H. pylori reinfection is rare 
in general population with annual prevalence of 1.97%. There 
is a report the most reinfection occurs within 2 years.
31 It is 
reasonable, therefore, to say that follow-up endoscopy is rec-108  Clin Endosc 2011;44:101-108
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ommended at 6 month interval for at least 2 years; more clini-
cal studies are required to determine by when the follow-up 
endoscopy is needed.
In conclusion, the remission rate of low grade gastric MALT 
lymphoma was 86% when using H. pylori eradication therapy 
only, which was a higher level than studies in Western coun-
tries. The possibility of H. pylori eradication success was in-
creased in patients with less neutrophil infiltration.
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